Key information

🔎 Fund Overview

Eyenovia, Inc. is an ophthalmic technology company. The Company is developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its potential for superior compliance versus standard eye drops. The Company’s commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi for mydriasis. Mydcombi is an FDA-approved fixed combination of the two pupil dilation drugs, tropicamide and phenylephrine, delivered with its Optejet technology. The product is indicted to induce mydriasis (pupil dilation) for routine diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroLine is its investigational proprietary microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or contraction of the pupil.